Small molecules

Small molecule pharmaceuticals have been the backbone of medical treatment since the inception of pharmacology. Scientific progress in drug discovery and increased clinical testing have inspired a plethora of small molecule drugs which are safe, efficacious, and easy to use. However, numerous diseases cannot be treated, or are not adequately treated, with current drugs. Animol Discovery has created a next generation combination of technologies that changes the paradigm of new drugs discovery for these unmet medical needs.

Small molecules

Small molecule pharmaceuticals have been the backbone of medical treatment since the inception of pharmacology. Scientific progress in drug discovery and increased clinical testing have inspired a plethora of small molecule drugs which are safe, efficacious, and easy to use. However, numerous diseases cannot be treated, or are not adequately treated, with current drugs. Animol Discovery has created a next generation combination of technologies that changes the paradigm of new drugs discovery for these unmet medical needs.

Releasing the potential of pharmaceuticals in animal health

Animol Discovery, based on the pioneering work of our exclusive partners X-Chem and ZebiAI, has developed a platform that is unique in the Animal Health industry. This platform builds on DNA-encoded chemical libraries in combination with advanced artificial intelligence/machine learning algorithms.

DNA-encoded libraries allow for a substantially accelerated ultra-high throughput screening process that can evaluate target and anti-target(s) activities simultaneously.

Artificial intelligence/machine learning built from the extremely clean datasets created by DNA-encoded libraries provides highly predictive algorithms and therefore unprecedented insights into structure-activity relationship right out of the screen. This enables us to take advantage of a hugely expanded chemical space for the selection of compounds with optimal properties guiding us to select the most promising drugs for our patients and speed up the delivery of innovation.


Pipeline

Since initiation of the first project in June 2020, Animol Discovery has completed several screens and has moved these projects to lead optimization. We are on track to complete up to ten more before screens the end of 2021 and–for the coming years–we will further increase the number of screens per year.